These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Viral infections and childhood asthma. Kimpen JL Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 2):S108-12. PubMed ID: 10988163 [No Abstract] [Full Text] [Related]
49. Palivizumab (Synagis) for prevention of RSV infection. Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488 [No Abstract] [Full Text] [Related]
50. Inhalation of corticosteroids after hospital care for respiratory syncytial virus infection diminishes development of asthma in infants. Hesselmar B; Adolfsson S Acta Paediatr; 2001 Mar; 90(3):260-3. PubMed ID: 11332164 [TBL] [Abstract][Full Text] [Related]
51. New strategies for control of respiratory syncytial virus infection. Nokes JD; Cane PA Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532 [TBL] [Abstract][Full Text] [Related]
53. Response to respiratory synctial virus. Hampp C; Winterstein AG South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631 [No Abstract] [Full Text] [Related]
54. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G; Porter T; Dillon S; Trill J; Ganguly S; Hart T; Davis C; Wyde P; Tempest P; Harris W Biochem Soc Trans; 1995 Nov; 23(4):1063-7. PubMed ID: 8654682 [No Abstract] [Full Text] [Related]
55. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Cabalka AK Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269 [TBL] [Abstract][Full Text] [Related]
56. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it? Sunnegårdh J Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482 [TBL] [Abstract][Full Text] [Related]
57. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Abarca K; Jung E; Fernández P; Zhao L; Harris B; Connor EM; Losonsky GA; Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920 [TBL] [Abstract][Full Text] [Related]
58. Viruses and atopic sensitization in the first years of life. Martinez FD Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 2):S95-9. PubMed ID: 10988160 [No Abstract] [Full Text] [Related]